Physician profile
David A Busch
NPI 1538288360
$3,217.65
in general payments reported to CMS, 2019-2025
18 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $47.22 · 2021: $348 · 2022: $304 · 2023: $788 · 2024: $791 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,281.86 | 2023-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Linq II |
| Novartis Pharmaceuticals Corporation | $698.13 | 2020-2025 | |
| Impulse Dynamics (USA) INC. | $381.44 | 2021-2023 | Optimizer |
| Pfizer INC. | $185.21 | 2019 | |
| Abiomed | $139.08 | 2025 | |
| Janssen Scientific Affairs, LLC | $105.76 | 2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.50 | 2022 | |
| Boston Scientific Corporation | $59.23 | 2025 | General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $48.97 | 2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $47.42 | 2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $44.92 | 2020-2024 | Xarelto |
| Amgen INC. | $40.61 | 2022-2023 | Repatha |
| Lilly USA, LLC | $30.90 | 2023-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.08 | 2025 | Jardiance |
| Novo Nordisk INC | $14.67 | 2024 | Ozempic, Rybelsus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $13.76 | 2020 | |
| Esperion Therapeutics, INC. | $13.11 | 2024 | Nexletol |
| Amarin Pharma, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.